Drug Trial Radar · NCT06085534
A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis
Last checked: Nov 19, 2026Latest source record: Oct 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
177
Actual
Start
Jan 6, 2022
Primary completion
Dec 6, 2022
Study completion Jun 20, 2023
Sponsor
- Lead sponsor
- Lynk Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study was to evaluate the safety and efficacy of multiple doses of LNK01001 monotherapy versus placebo in the treatment of adults with active Ankylosing Spondylitis
Conditions
- Ankylosing Spondylitis
Interventions
LNK01001Drug
Capsules for oral use
PlaceboDrug
Capsules for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving 40% Improvement in ASAS Score at Week 12.Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.